Store

Home | Store | Cell and Gene Therapy Deals, 2022

Cell and Gene Therapy Deals, 2022

Publication Date: February 17, 2022

SKU: 22-054

Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Funding and Investments, Life Science, Mergers and Acquisitions (M&A), Oncology and Cancer

Pages: 155

SKU: 22-054

The cell and gene therapy (CGT) sector has experienced remarkable growth, with funding reaching $70 billion in 2021. As barriers to entry lower and the number of approved therapies with proven track records increases, over a thousand companies have entered or expanded within this dynamic field. Keeping up with this rapidly evolving industry is essential, and Kalorama Information’s latest report, Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments, 2022, provides comprehensive insights into the myriad deals shaping the CGT landscape.

 

Key Highlights:

  • Funding and Investments: Detailed analysis of the financial influx into CGT-related companies, including IPOs, SPACs, venture capital, and private funding.
  • Strategic Deals: Insight into mergers & acquisitions, strategic investments, technology and research collaborations, and licensing agreements.
  • Operational Transactions: Examination of manufacturing and supply chain deals, public outreach efforts, consumer education, philanthropy, and distribution partnerships.
  • Market Dynamics: Breakdown of restructurings, joint ventures, terminations, and spinoffs impacting the CGT sector.
  • Quarterly Analysis: Charts illustrating the frequency and types of deals throughout 2021, providing a clear view of market trends and activity changes per quarter.

 Why This Report is Essential:

  • Comprehensive Coverage: Tracks hundreds of cell and gene therapy deals, categorizing them into a usable format for easy reference.
  • Market Insight: Offers in-depth analysis of key deals and strategic movements within the CGT industry.
  • Investor Guidance: Provides valuable information for investors looking to understand the funding landscape and identify opportunities.

 

Additional Features:

  • Vendor Profiles: Detailed profiles of leading companies involved in the CGT market.
  • Visual Data Representation: Charts and graphs that visually represent deal activities and trends.
  • Expert Analysis: Insights from Kalorama’s experienced analysts, offering expert perspectives on market developments.

 

Table: Total Quarterly Funding, By 2021 Quarter, By Type of Funding (in millions $) (%)

Category Q1 Q2 Q3 Q4 Total %
M&A $XX Million $XX Million $XX Million $XX Million $XX Million XX%
VC/ Private $XX Million $XX Million $XX Million $XX Million $XX Million XX%
IPO/ FPO $XX Million $XX Million $XX Million $XX Million $XX Million XX%
SPAC $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Strat. Investment* $XX Million $XX Million $XX Million $XX Million $XX Million XX%
Total $XX Million $XX Million $XX Million $XX Million $XX Million XX%

Source: Kalorama Information

For further details and to purchase directly, please contact us.

Table of Contents

Chapter 1: Executive Summary

Introduction

$70 Billion in Funding During 2021

  • Table 1-1: Total Quarterly Funding, By 2021 Quarter, By Type of Funding [/M&A; Venture Capital/Private; IPO/FPO; and SPAC] (note: also Strat. Inv. $600M min) ($M) (%)
  • Figure 1-1: Total Quarterly Funding, By 2021 Quarter, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M)

Quarterly Funding in 2021

  • Figure 1-2: Q1 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
  • Figure 1-3: Q2 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
  • Figure 1-4: Q3 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
  • Figure 1-5: Q4 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)

903 CGT Announcements from January 2021 through January 2022

  • Table 1-2: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)

Uptick in Collaborations, Acquisitions, and Manufacturing/Supply Chain Deals Highlight Activity in Cell and Gene Therapy

  • Figure 1-6: Most Frequent Types of Deals, by 2021 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)

A Look at Less Frequent CGT Deal Types

  • Figure 1-7: Lower Frequency Deal Types, by 2021 Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
  • Table 1-3: Monthly Count of Deals [January 2021-January 2022], By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number, n=903) (%)
  • Figure 1-8: Total Deals per Month, January 2021-January 2022 (total number)
  • Figure 1-9: Most Frequent Types of Deals, by Month [January 2021-January 2022], by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
  • Figure 1-10: Lower Frequency Deal Types, by Month [January 2021-January 2022], by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
  • Figure 1-11: Acquisition Amount, by Quarter [January 2021-January 2022] ($M)
  • Figure 1-12: Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
  • Figure 1-13: IPO/FPO Amount, by Quarter [January 2021-December 2021] ($M)
  • Figure 1-14: SPAC Amount, 2021 ($M)

 

Chapter 2: Venture Capital & Private Funding

VC/Private Funding in Flux

  • Table 2-1: Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022],  By Region [North America, Europe, APAC, Rest of World] ($M)
  • Figure 2-1: Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022],  By Region [North America, Europe, APAC, Rest of World] ($M)
  • Figure 2-2: Venture Capital/Private Funding Round Amount, By Quarter [January 2021-January 2022], ($M)
  • Table 2-2: Venture Capital/Private, January 2022
  • Table 2-3: Venture Capital/Private, Q4 2021
  • Table 2-4: Venture Capital/Private, Q3 2021
  • Table 2-5: Venture Capital/Private, Q2 2021
  • Table 2-6: Venture Capital/Private, Q1 2021

 

Chapter 3: Strategic Investments

Strategic Investments in Cell and Gene Therapy

  • Table 3-1: Strategic Investments, January 2021-January 2022

 

Chapter 4: IPOs, FPOs, & SPACs

North America Sees Majority of Proceeds from IPOs, FPOs, and SPACs

  • Table 4-1: Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe)  ($M)
  • Figure 4-1: Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe)  ($M)
  • Figure 4-2: IPO/FPO Amount, By Quarter [January 2021-January 2022] ($M)
  • Table 4-2: Disclosed Quarterly SPAC Funding Portion  ($M)
  • Figure 4-3: Disclosed Q1-Q4 and January 2022 SPAC Funding Portion  ($M)
  • Table 4-3: IPO/FPO Deals, Q4 2021
  • Table 4-4: IPO/FPO Deals, Q3 2021
  • Table 4-5: IPO/FPO Deals, Q2 2021
  • Table 4-6: IPO/FPO Deals, Q1 2021
  • Table 4-7: SPAC Piece, January 2021-January 2022 ($M)
  • Figure 4-4: SPAC Amount, 2021 ($M)

 

Chapter 5: Mergers & Acquisitions (M&A)

2021 Sees Spike in M&A Activity During Q3

  • Table 5-1: Quarterly Merger and Acquisition Totals, January 2021-January 2022 ($M)
  • Figure 5-1: Acquisition Amount, By Quarter [January 2021-January 2022], ($M)
  • Table 5-2: Mergers and Acquisitions, January 2022 ($M)
  • Table 5-3: Mergers and Acquisitions, Q4 2021 ($M)
  • Table 5-4: Mergers and Acquisitions, Q3 2021 ($M)
  • Table 5-5: Mergers and Acquisitions, Q2 2021 ($M)
  • Table 5-6: Mergers and Acquisitions, Q1 2021 ($M)

 

Chapter 6: Technology/Research/Strategic Collaborations

CGT Market Sees an Assortment of Collaborations

  • Table 6-1: Technology/Research/Strategic Collaboration Deals, January 2021-January 2022

 

Chapter 7: Licensing

A Look at Licensing in the Cell and Gene Therapy Market

  • Table 7-1: Licensing Deals, January 2021-January 2022

 

Chapter 8: Manufacturing and Supply Chain

Examining Manufacturing and Supply Chain Management Activity in CGT

  • Table 8-1: Manufacturing and Supply Chain Deals, January 2021-January 2022

 

Chapter 9: Public Outreach, Consumer Education, & Philanthropy

CGT Market Has Dozens of Announcements Related to Public Outreach, Patient/Consumer Education, and Philanthropy

  • Table 9-1: Outreach, Education, & Philanthropy Deals, January 2021-January 2022

 

Chapter 10: Distribution & Co-Marketing

A Look at CGT Distribution and Co-Marketing Deals

  • Table 10-1: Distribution & Co-Marketing Deals, January 2021-January 2022

 

Chapter 11: Other – Conclusion, Restructuring, JV, Termination, Spinoffs

A Look at Other Types of Deals Impacting Cell and Gene Therapy

  • Table 11-1: Restructuring, JV, Termination, Spinoffs Deal, January 2021-January 2022

Our Knowledge Center provides access to

all market reports